---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274515"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:01:41.440445+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# INOVIO gets FDA breakthrough therapy for INO-3107; BLA on accelerated path without Phase 3 trial

## Summary
- FDA granted Breakthrough Therapy designation for INO-3107 to treat Recurrent Respiratory Papillomatosis (RRP).
- FDA confirmed Phase 1/2 trial data can support BLA submission under accelerated approval; no Phase 3 required.
- Cash, cash equivalents and short-term investments of $167.5M as of September 30, 2023.
- INOVIO planning to submit BLA under accelerated approval; type B meeting requested for Q4 2023.
- Commercialization strategy accelerated for potential earlier launch of INO-3107 if approved.

## SEC filing metadata
- accession: 0001193125-23-274515
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312523274515/0001193125-23-274515-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312523274515/d295356d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274515
- JSON: https://secwatch.observer/filing/0001193125-23-274515.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274515.txt

## Key facts
- Earnings Releases
  INOVIO PHARMACEUTICALS, INC. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312523274515/0001193125-23-274515-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.